Log in

Relevant bibliographies by topics / Chucai / Journal articles

Journal articles on the topic 'Chucai'

To see the other types of publications on this topic, follow the link: Chucai.

Author: Grafiati

Published: 10 December 2022

Last updated: 28 January 2023

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Chucai.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Hui, Ming Tak Ted. "Journeys to the West: Travelogues and Discursive Power in the Making of the Mongol Empire." Journal of Chinese Literature and Culture 7, no. 1 (April 1, 2020): 60–86. http://dx.doi.org/10.1215/23290048-8313520.

Full text

Abstract:

Abstract Before the Mongol conquest in 1279, numerous envoys were sent from the Southern Song court to its neighboring states. Their purpose was to evaluate and tame foreign territories and alien peoples and thereby reduce their threat to Song culture, and the travelogues resulting from these journeys were often “utilitarian” in style. The Record of the Perfected Master Changchun's Journey to the West (Changchun zhenren xiyou ji 長春真人西遊記), however, deserves special attention for its nuanced handling of a complex cultural-political power dynamics. Its compiler, Li Zhichang, was a leader in the Quanzhen sect, and his travelogue documents the journey of his master, Qiu Chuji, at the invitation of Chinggis (Genghis) Khan. Li's text illustrates the tension of competing political and cultural authorities: while the Mongols were becoming the source of political authority, the Taoists still owned the discursive power. The author argues that Li deliberately adopted a narrative strategy that conceded the Mongol claim to political legitimacy while simultaneously asserting Taoism's cultural dominance over the Mongols. The article also juxtaposes Li's work with the travel record by Yelü Chucai, a Khitan adviser to the Mongols who traveled with Chinggis Khan during his western military expeditions. Although Yelü's travelogue is often read as a rebuttal to Li Zhichang's work, a closer look reveals how Yelü appropriated Li's strategy for his own agenda: to justify Mongols' invasion of Central Asia while highlighting the cultural values shared between the Mongols and the Han Chinese. Both works employ rhetorical strategies that laid the foundation for political discourse affirming the Mongol-Yuan dynastic legitimacy.

APA, Harvard, Vancouver, ISO, and other styles

2

Galbayar, Gombosyryn, and Maria P. Petrova. "The Hidden Meanings and Poetic Features of the Treatise “Činggis-un yisün örlüg-tei öničin köbegün-ü čečelegsen šastir”." Vestnik of Saint Petersburg University. Asian and African Studies 14, no. 3 (2022): 488–506. http://dx.doi.org/10.21638/spbu13.2022.307.

Full text

Abstract:

The extant variants of the now-lost treatise Činggis-un yisün örlüg-tei önöčin köbegün-ü čečelegsen šastir are attested in the 17th-18th century Mongolian historical chronicles Altan Tobči / The Golden Chronicle (1655) by Lubsangdanjin and the Bolor Erike / “Crystal Rosary” / (1774-1775) by Rasipungsug. This article addresses the history of transmission, translations, and studies of this text, and demonstrates that the Činggis-un yisün örlüg-tei öničin köbegün-ü čečelegsen šastir is not merely an account of Chinggis Khan’s discussion with his nine high officials about the benefits and evils of alcohol, but contains deeper hidden meanings. Specifically, this paper offers the following four findings: First, based on comparison with Mongolian historical sources, this paper clarifies the origins of Chinggis Khan’s nine high officials, how they befriended Chinggis Khan, their merits and accomplishments, and their deaths. Based on these sources, we have determined that the events described in the Činggis-un yisün örlüg-tei öničin köbegün-ü čečelegsen šastir date to 1206-1207. Second, this paper discusses the hidden meaning that Bo’orchu, Muqali, Boqorul, Jebe, who wish to abstain from alcohol and diligently perform their duties, befriended Chinggis Khan in their childhood without seeking any benefit, were fully trustworthy officials, whereas Sorqan-Shira, Jelme, Yelü Chucai, Qara Kiru and Shigi-Qutuqu - who, in their own words, wish to drink alcohol and revel - befriended Chinggis Khan later out of self-benefit, and were untrustworthy officials. Third, the paper discusses the symbolism of the order of the speakers’ words on alcohol as it relates to the ranks of Chinggis Khan’s officials, as well as Mongolian cultural symbolism relating to directions. Fourth, based on the debate in the text between the orphan boy, wise nobleman Chindagha, and Chinggis Khan, this paper discusses the fact that one reason Chinggis Khan’s state was powerful is that he listened to average people and he was able to reflect their ideas in national affairs. Fifth, this paper demonstrates that the text retains important features of deep hidden meaning and poetic verse characteristic of 13th century Mongolian literature.

APA, Harvard, Vancouver, ISO, and other styles

3

Mullard, Asher. "Chugai reports Actemra deaths." Nature Biotechnology 27, no. 5 (May 2009): 407. http://dx.doi.org/10.1038/nbt0509-407.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Saliba, Georges. "Joseph Chucri Moubarak : 1931 - 2015." Lebanese Medical Journal 63, no. 4 (2015): 232. http://dx.doi.org/10.12816/0017973.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

TREMBLAY, JEAN-FRANÇOIS. "ROCHE TO BUY STAKE IN CHUGAI." Chemical & Engineering News 79, no. 51 (December 17, 2001): 12. http://dx.doi.org/10.1021/cen-v079n051.p012a.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Zhang, Xuecheng, and Yingying Bo. "The Exegetical Research on “Chuci Shu”." Journal of Chinese Language and Literature 106 (October 31, 2017): 65–84. http://dx.doi.org/10.25021/jcll.2017.10.106.65.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Jaenichen, Hans-Rainer. "{BLR 1463} EPO - Amgen - Chugai - Erythropoietin - rDNA." Biotechnology Law Report 12, no. 3 (May 1993): 237–48. http://dx.doi.org/10.1089/blr.1993.12.237.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Halluin, Albert P., and Harold C. Wegner. "{BLR 1156} Patent Litigation - Amgen/Chugai - Scripps/Genentech." Biotechnology Law Report 10, no. 3 (January 1991): 191–214. http://dx.doi.org/10.1089/blr.1991.10.191.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

Jenkinson, Biddy. "Fand agus an Chuach." Comhar 61, no. 4 (2001): 26. http://dx.doi.org/10.2307/25574219.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

Levun, N. V., and O. K. Stepanenko. "PHRASEOLOGICAL UNITS IN THE NOVEL «MARUSIA CHURAI» BY LINA KOSTENKO." Тrаnscarpathian Philological Studies 1, no. 13 (2020): 73–76. http://dx.doi.org/10.32782/tps2663-4880/2020.13-1.14.

Full text

APA, Harvard, Vancouver, ISO, and other styles

11

Cully, Megan. "Galderma pursues 'itchy cytokine' by licensing antibody from Roche's Chugai." Nature Reviews Drug Discovery 15, no. 9 (August 30, 2016): 597. http://dx.doi.org/10.1038/nrd.2016.165.

Full text

APA, Harvard, Vancouver, ISO, and other styles

12

Garcia, Carol. "Janelas: Estação Chueca do metrô." dObra[s] – revista da Associação Brasileira de Estudos de Pesquisas em Moda 3, no. 5 (February 10, 2009): 33. http://dx.doi.org/10.26563/dobras.v3i5.304.

Full text

Abstract:

Em 1591, num tratado intitulado Sobre os vínculos em geral, o filósofo italiano Giordano Bruno (1548-1600) já apontava que o ambiente é parcialmente responsável pela natureza da ligação entre dois ou mais elementos. A cidade de Madri, na Espanha, parece ter entendido isso muito bem, criando processos de interação social a partir dos distintos sistemas de vínculos estabelecidos entre seus moradores. Mas como são elaborados esses vínculos comunicativos? Design gráfico, visual merchandising, gastronomia e moda, juntos, formam a razão de ser fraternal de um bairro colorido com os tons do arco-íris, a Chueca. Cercada pelas ruas Barquillo, Hortaleza, Gran Vía e Alfonso VI, a região é famosa mundo afora. Afinal, foi lá que surgiu, nos anos 1980, o fenômeno conhecido como La Movida, agito pós-franquista que transformou a então sisuda e cinzenta Madri com as cores de Agatha Ruiz de La Prada, a musicalidade deMiguel Bosé e a ironia de Pedro Almodóvar. (....)

APA, Harvard, Vancouver, ISO, and other styles

13

OGUOMA, O. N., and D. J. BILLAU. "Gripping force of diaphragm chucks." International Journal of Production Research 25, no. 7 (July 1987): 995–1011. http://dx.doi.org/10.1080/00207548708919891.

Full text

APA, Harvard, Vancouver, ISO, and other styles

14

Breatnach, Pádraig. "An Chuach: sliocht as scéal." Comhar 51, no. 8 (1992): 18. http://dx.doi.org/10.2307/25571857.

Full text

APA, Harvard, Vancouver, ISO, and other styles

15

Kalkowski, G., S. Risse, G. Harnisch, and V. Guyenot. "Electrostatic chucks for lithography applications." Microelectronic Engineering 57-58 (September 2001): 219–22. http://dx.doi.org/10.1016/s0167-9317(01)00519-6.

Full text

APA, Harvard, Vancouver, ISO, and other styles

16

Yamnikov, A. S., and A. O. Chuprikov. "Chucks for thin-walled blanks." Russian Engineering Research 35, no. 11 (November 2015): 838–40. http://dx.doi.org/10.3103/s1068798x15110179.

Full text

APA, Harvard, Vancouver, ISO, and other styles

17

Jung, Udo O. H. "Chudak, Sebastian (Hrsg.): Fremdsprachenunterricht – omnimedial?" Informationen Deutsch als Fremdsprache 41, no. 2-3 (June 1, 2014): 197–99. http://dx.doi.org/10.1515/infodaf-2014-2-321.

Full text

APA, Harvard, Vancouver, ISO, and other styles

18

Wright, D. R. "Manufacturing issues of electrostatic chucks." Journal of Vacuum Science & Technology B: Microelectronics and Nanometer Structures 13, no. 4 (July 1995): 1910. http://dx.doi.org/10.1116/1.588108.

Full text

APA, Harvard, Vancouver, ISO, and other styles

19

Charrier, Reynaldo, Alvaro N. Chávez, Sara Elgueta, Gérard Hérail, John J. Flynn, Darin A. Croft, André R. Wyss, Rodrigo Riquelme, and Marcelo García. "Rapid tectonic and paleogeographic evolution associated with the development of the Chucal anticline and the Chucal-Lauca Basin in the Altiplano of Arica, northern Chile." Journal of South American Earth Sciences 19, no. 1 (May 2005): 35–54. http://dx.doi.org/10.1016/j.jsames.2004.06.008.

Full text

APA, Harvard, Vancouver, ISO, and other styles

20

Rodriguez, Luis J. "Scenes: Tia Chuca Press: An interview with Luis J. Rodriguez." American Book Review 42, no. 5 (2021): 35. http://dx.doi.org/10.1353/abr.2021.0094.

Full text

APA, Harvard, Vancouver, ISO, and other styles

21

Kim, Inho. "Understanding of Chuci(楚辭) in the Han(漢) dynasty." JOURNAL OF CHINESE HUMANITIES 66 (August 31, 2017): 219–39. http://dx.doi.org/10.35955/jch.2017.08.66.219.

Full text

APA, Harvard, Vancouver, ISO, and other styles

22

De Santo, Toni L., Mary F. Willson, Kathryn E. Sieving, and Juan J. Armesto. "Nesting Biology of Tapaculos (Rhinocryptidae) in Fragmented South-Temperate Rainforests of Chile." Condor 104, no. 3 (August 1, 2002): 482–95. http://dx.doi.org/10.1093/condor/104.3.482.

Full text

Abstract:

Abstract We studied the effect of forest fragmentation on the nesting biology and reproductive success of three species of tapaculos (Rhinocryptidae) in relation to forest size, edge effects, and disturbance from livestock or logging over a 6-year period (1993–1999) in Chilean temperate rainforest. Overall, Mayfield nest success (n = 360) among the three species ranged from 64% to 85%, and predation accounted for 64% of nest losses. Considering all types of losses, nest mortality was similar in fragmented and unfragmented forest, but predation was higher in fragmented forest. Successful nest sites of the Chucao Tapaculo (Sclerochilus rubecula; the species with the largest sample size) were nearer forest edges, better concealed, closer to the ground, and had longer entrance tunnels, on average, than depredated nests. Reuse of nest sites by chucaos was more common in forest fragments with livestock or logging than in undisturbed forests, but reuse was independent of forest size. Success of second broods was lower in reused nest sites than in new nest sites. Nestling growth in fragmented forest and forest with livestock or logging activity was similar to that in unfragmented and undisturbed forest. Clutch size was typically two, but birds nesting at low densities in forest fragments often laid three-egg clutches following a nest failure. In addition to negative effects of forest fragmentation during nesting (greater use of less-successful nest sites, higher nest predation), there was an indication that early juvenile survival was lower in forest fragments. Biología de Nidificación de Tapaculos (Rhinocryptidae) en la Selva Lluviosa Templada Fragmentada de Chile Resumen. Durante seis años (1993–1999) estudiamos los efectos de la fragmentación de bosques templados del sur de Chile sobre la biología y éxito reproductivo de tres especies de tapaculos (Rhynocriptidae) en relación al tamaño del fragmento boscoso, efectos de borde, y perturbación por ganado doméstico y tala de árboles. En general, el éxito de nidificación (n = 360) estimado por el método Mayfield para las tres especies varió entre 64% y 85%. La depredación explicó un 64% de las pérdidas de nidos. Tomando en cuenta todas las causas de mortalidad, la pérdida de nidos fue equivalente en bosques fragmentados y continuos, pero la depredación fue mayor en bosques fragmentados. Los sitios de nidificación exitosa de Sclerochilus rubecula (chucao; la especie con el mayor número de muestras) se encontraron, en promedio, más cerca de los bordes, mejor ocultos, más cerca del suelo y con túneles de entrada más largos que los nidos depredados. La reutilización de nidos por parte de los chucaos fue más común en los fragmentos perturbados por tala de árboles o pisoteo de ganado que en bosques no perturbados, pero fue independiente del tamaño del fragmento. El éxito de la segunda nidada fue menor en nidos re-utilizados que en nidos nuevos. El crecimiento de los juveniles en los nidos ubicados en bosques fragmentados y perturbados fue similar al del observado en los bosques continuos no perturbados. El número de crías de los chucaos fue típicamente dos, pero las aves que anidaron en fragmentos boscosos, donde la densidad local era baja, frecuentemente pusieron tres huevos por nido luego de un intento de nidificación fallido. Además de los efectos negativos de la fragmentación del bosque durante el período de nidificación (i.e., mayor uso de sitios de nidificación inseguros, mayor depredación de nidos), la sobrevivencia temprana de los juveniles sería menor en fragmentos boscosos.

APA, Harvard, Vancouver, ISO, and other styles

23

Abdullah, Siti Nor Fazillah, Safari Mat Desa, Suriyani Awang, Ahmad Husaini Sulaiman, Azimah Ismail, Hafizan Juahir, Azman Mat Jusoh, et al. "Impact of Flood Mitigation Project on the River Water Salinity." Trends in Sciences 19, no. 15 (July 24, 2022): 5382. http://dx.doi.org/10.48048/tis.2022.5382.

Full text

Abstract:

The impact of flood mitigation project in the Kemaman River Basin was assessed in this study. Salinity intrusion was simulated in the study area by 1D numerical model. A 1-D hydrodynamic model coupled with a salinity model was used to analyze the salinity intrusion within Chukai River after the implementation of the flood mitigation project. The model was calibrated and validated using the data measured in Chukai River at 3 points from January 2007 until August 2013. Water quality simulation of salinity has been carried out once an excellent hydrodynamic model was established. The simulated river flow was reasonably matched to the measured data with R2 value 0.88, 0.92 and 0.82, respectively. Results suggest that after the realignment of Chukai River, the seawater intrudes further to the upstream river, causing the increasing salinity in the river about 10 - 15 ppt. However, with the floodway development, the channel would allow more water from Kemaman River being discharged into Chukai River. Increased in the volume of water in Chukai River has led to seawater dilution. Further, it invades the unique stretch of Chukai River and takes the salinity back to the initial state. Findings from the implementation of the flood mitigation project in the Kemaman river basin has benefitted the local society, watershed, and the surrounding biota ecosystems. Importantly, a greater prevention with the risk of repetitive flood damage to the buildings and structures in Kemaman area which has significantly achievable. HIGHLIGHTS Salinity model is used for flood mitigation project High salinity in Chukai river resulted from seawater intrusion Hydrodynamic model is to assess the water quality simulation

APA, Harvard, Vancouver, ISO, and other styles

24

Abdullah, Siti Nor Fazillah, Safari Mat Desa, Suriyani Awang, Ahmad Husaini Sulaiman, Azimah Ismail, Hafizan Juahir, Azman Mat Jusoh, et al. "Impact of Flood Mitigation Project on the River Water Salinity." Trends in Sciences 19, no. 15 (July 24, 2022): 5382. http://dx.doi.org/10.48048/tis.2022.5382.

Full text

Abstract:

The impact of flood mitigation project in the Kemaman River Basin was assessed in this study. Salinity intrusion was simulated in the study area by 1D numerical model. A 1-D hydrodynamic model coupled with a salinity model was used to analyze the salinity intrusion within Chukai River after the implementation of the flood mitigation project. The model was calibrated and validated using the data measured in Chukai River at 3 points from January 2007 until August 2013. Water quality simulation of salinity has been carried out once an excellent hydrodynamic model was established. The simulated river flow was reasonably matched to the measured data with R2 value 0.88, 0.92 and 0.82, respectively. Results suggest that after the realignment of Chukai River, the seawater intrudes further to the upstream river, causing the increasing salinity in the river about 10 - 15 ppt. However, with the floodway development, the channel would allow more water from Kemaman River being discharged into Chukai River. Increased in the volume of water in Chukai River has led to seawater dilution. Further, it invades the unique stretch of Chukai River and takes the salinity back to the initial state. Findings from the implementation of the flood mitigation project in the Kemaman river basin has benefitted the local society, watershed, and the surrounding biota ecosystems. Importantly, a greater prevention with the risk of repetitive flood damage to the buildings and structures in Kemaman area which has significantly achievable. HIGHLIGHTS Salinity model is used for flood mitigation project High salinity in Chukai river resulted from seawater intrusion Hydrodynamic model is to assess the water quality simulation

APA, Harvard, Vancouver, ISO, and other styles

25

KANNO, Seiichiro, and Tatehito USUI. "Performance Evaluation of Bipolar Electrostatic Chucks." SHINKU 42, no. 9 (1999): 840–44. http://dx.doi.org/10.3131/jvsj.42.840.

Full text

APA, Harvard, Vancouver, ISO, and other styles

26

Chías Navarro, Pilar. "Fernando Chueca Goitia. Una biografía gráfica." EGA Revista de Expresión Gráfica Arquitectónica 27, no. 44 (March 24, 2022): 254–75. http://dx.doi.org/10.4995/ega.2022.17179.

Full text

Abstract:

Profesor, arquitecto, urbanista, investigador, infatigable defensor del patrimonio, orador elocuente y prolífico ensayista son algunas de las facetas que caracterizan la obra de Fernando Chueca Goitia (1911-2004). A través de esta biografía gráfica, en la que las reflexiones acompañan a los apuntes de viaje, a los dibujos de levantamiento, de análisis y de proyecto, propongo una revisión de los aspectos más destacables de su larga trayectoria en relación con la arquitectura, la ciudad y el patrimonio.

APA, Harvard, Vancouver, ISO, and other styles

27

Nieto, Enrique. "“Chucho” Pérez Martín: un amigo entrañable." Revista Alergia México 61, no. 3 (June 30, 2014): 127–28. http://dx.doi.org/10.29262/ram.v61i3.35.

Full text

Abstract:

Un severo choque anafiláctico, un suceso alérgico a fin de cuentas, me puso en contacto con Jesús Pérez Martín, allá por 1970. Le llamaron como consultante para revisar mi caso: enseguida de su diagnóstico decidió permanecer cerca, sentado en un silla junta a la cama de Urgencias, para ver mi evolución. Durante la espera sacó unas cuartillas arrugadas y comenzó a corregirlas y a escribir al reverso. ¿Acaso era corrector como yo? No: editaba una revista de Alergia, según me comentó.

APA, Harvard, Vancouver, ISO, and other styles

28

Bagla, P. "CLIMATE FORECASTING: India Chucks Monsoon Model." Science 309, no. 5733 (July 15, 2005): 365a. http://dx.doi.org/10.1126/science.309.5733.365a.

Full text

APA, Harvard, Vancouver, ISO, and other styles

29

Kalkowski, Gerhard, Stefan Risse, and Sandra Müller. "Flatness characterization of EUV mask chucks." Microelectronic Engineering 84, no. 5-8 (May 2007): 737–40. http://dx.doi.org/10.1016/j.mee.2007.01.003.

Full text

APA, Harvard, Vancouver, ISO, and other styles

30

Zikpi, Monica E. M. "WANTON GODDESSES TO UNSPOKEN WORTHIES: GENDERED HERMENEUTICS IN THE CHU CI ZHANGJU." Early China 41 (2018): 333–74. http://dx.doi.org/10.1017/eac.2018.1.

Full text

Abstract:

AbstractThe influential Chu ci zhangju 楚辭章句, the earliest received edition of the foundational poetry anthology Chuci 楚辭, performs a distinct gender bias in its exegesis of deities, and this bias accords with the Eastern Han ideology of the editor Wang Yi 王逸 (2nd c. CE) more than with immanent features of the original Warring States texts. The gender bias is an essential feature of Wang Yi’s canonization of the Chuci, and it lays the groundwork of the allegorical tradition of interpreting the Chuci. This paper analyzes the zhangju presentation of archetypal Chuci texts to elucidate the hermeneutic transformation of gender and religion in early China, comparing the Eastern Han exegeses with earlier and later interpretations, immanent textual features, and fresh perspectives on Warring States and Han culture that have emerged from archeological evidence. The analysis demonstrates that the Chuci zhangju treats the male deities more literally than the female deities, reflecting the reduction in status of goddesses in late Han discourse. The history of gender ideology is an essential critical lens for understanding the Chuci and the tradition that emerged from it.

APA, Harvard, Vancouver, ISO, and other styles

31

HOLIKOVA, Nataliia. "«LINGUOCULTUREMA «MARUSIA CHURAI» IN THE UKRAINIAN LITERATURE OF THE XIX – XX CENTURIES»." Culture of the Word, no. 92 (2020): 36–51. http://dx.doi.org/10.37919/0201-419x-2020.92.3.

Full text

Abstract:

The article describes the folklore and literary evolution of the historical figure Marusia Churai in the prose, poetic, dramatic works of writers of the XIX– XX centuries. The concept of «folk song» is actualized, where folklorisms have a text-centric purpose for linguistic portrayal of the studied character. It is noted that Marusia Churai was the probable author of several dozen songs, which are now considered folk, and that the history of entering the literature of the author of the songs began with the folk ballad «Oh, don’t go, Hryts», which echoes similar pagan mythological legends. Based on the research of famous scientists, all the author’s texts, integrated with the plot of Hrits’s poisoning, are divided into two groups: 1) those that freely interpret the ballad; 2) those in which the content of the folk song is intertwined with ancient legends about Marusia Churai. A comparative analysis of semantic-semantic transformations, indicative of individual-author verbalization of thought in a number of artistic texts. Emphasis is placed on the novel «Marusia, Malorussian Sappho» by O. Shakhovskyi and on the historical novel in verse «Marusia Churai» by L. Kostenko. These are key works in which the precedent name of the author of the songs reflects the essence of the linguistic and aesthetic signs of Ukrainian culture, plays the role of a mythologeme or linguoculture, respectively. In conclusion, it is emphasized that Ukrainian society, being at the turn of worldviews, needs the protection of ethnolinguistic cultural values that maintain the connection of generations, accumulate the historical memory of the people.

APA, Harvard, Vancouver, ISO, and other styles

32

Storella, John. "{BLR 1750} Amgen v. Chugai - Fiers v. Revel - In re Bell - Patents." Biotechnology Law Report 13, no. 4 (July 1994): 459–67. http://dx.doi.org/10.1089/blr.1994.13.459.

Full text

APA, Harvard, Vancouver, ISO, and other styles

33

CARMO, L. F. R., F. C. VASCONCELLOS, W. F. MENEZES, and E. C. VASCONCELLOS. "Analysis of Instability Indexes for Intense, Moderate and low/no Rain in Southern and Southeastern Regions of Brazil." Anuário do Instituto de Geociências - UFRJ 42, no. 1 (May 13, 2019): 769–82. http://dx.doi.org/10.11137/2019_1_769_782.

Full text

APA, Harvard, Vancouver, ISO, and other styles

34

Fujii, T., T. Atsumi, N. Okamoto, N. Takahashi, N. Tamura, A. Nakajima, A. Nakajima, et al. "AB0249 SAFETY OF BARICITINIB IN JAPANESE PATIENTS WITH RHEUMATOID ARTHRITIS (RA): THE 2020 INTERIM REPORT FROM ALL-CASE POST MARKETING SURVEILLANCE IN CLINICAL PRACTICE." Annals of the Rheumatic Diseases 80, Suppl 1 (May 19, 2021): 1150.1–1150. http://dx.doi.org/10.1136/annrheumdis-2021-eular.433.

Full text

Abstract:

Background:An all-case post marketing surveillance (PMS) of baricitinib (Bari), that started in Sep 2017, collects safety and effectiveness for the first 24 wks of treatment and continues to collect serious adverse events (SAEs) for 3 yrs.Objectives:To evaluate Bari safety in RA patients (pt) in clinical practice.Methods:We report pt baseline demographics and adverse events (AEs) up to 24 wks for pts whose case report files for 24-wk data were completed as of Jun 2020.Results:Data from 3445 pts were analyzed (females=80%, mean age=64yr, mean RA duration 12yr). Bari dose regimen was as follows: 4mg, 60%, 2mg, 27%, 4mg→2mg, 5%, 2mg→4mg, 5%, and others, 2%. Concomitant use of MTX and glucocorticoid was 65% and 48%, respectively. 74% continued treatment for 24 wks. AE and SAE were recognized in 887 (26%) and 122 pts (4%), respectively. 6 pts died of pneumonia, aspiration pneumonia, bacterial pneumonia, cerebral infarction/ILD/aspiration pneumonia, adenocarcinoma, and colorectal cancer. Major AEs were as follows: herpes zoster=3%, liver dysfunction=3%, serious infection=1%, anemia=1%, hyperlipidemia=1%, malignancy=0.3%, interstitial pneumonia=0.2%, MACE=0.1%, and VTE=0.1%.Conclusion:Data do not show new safety concerns and encourage guideline-compliant use of Bari.Disclosure of Interests:Takao Fujii Speakers bureau: Chugai Pharmaceutical Co. Ltd.; Eisai Co. Ltd; Eli Lilly Japan K.K.; Janssen Pharmaceutical K.K.; Ono Pharmaceutical Co. Ltd., Consultant of: Asahikasei Pharma Corp, Grant/research support from: Asahikasei Pharma Corp; AbbVie Japan GK; Chugai Pharmaceutical Co. Ltd., Eisai Co. Ltd; Eli Lilly Japan K.K.; Mitsubishi-Tanabe Pharma Co.; Ono Pharmaceutical Co., Ltd., Tatsuya Atsumi Speakers bureau: AbbVie Japan GK; Astellas Pharma Inc.; Bristol-Myers Squibb Co. Ltd; Chugai Pharmaceutical Co. Ltd.; Daiichi Sankyo Co. Ltd.; Eisai Co. Ltd.; Eli Lilly Japan K.K.; Mitsubishi Tanabe Pharma Co.; Pfizer Japan Inc.; Takeda Pharmaceutical Co. Ltd., UCB Japan Co. Ltd., Consultant of: AbbVie Japan GK; AstraZeneca plc.; Boehringer Ingelheim Co. Ltd.; Medical & Biological Laboratories Co. Ltd.; Novartis Pharma K.K.; Ono Pharmaceutical Co. Ltd.; Pfizer Japan Inc., Grant/research support from: Astellas Pharma Inc., Alexion Inc.; Chugai Pharmaceutical Co. Ltd., Daiichi Sankyo Co. Ltd., Mitsubishi Tanabe Pharma Co., Otsuka Pharmaceutical Co., Ltd.Pfizer Japan Inc.; Takeda Pharmaceutical Co. Ltd., Nami Okamoto Speakers bureau: AbbVie Japan GK; Asahikasei Pharma Co.; AYUMI Pharmaceutical Co.Eisai Co. Ltd; Bristol-Myers Squibb Co. Ltd.; Eli Lilly Japan K.K.; Mitsubishi-Tanabe Pharma Co.; Pfizer Japan Inc.Sanofi K.K.; Chugai Pharmaceutical Co. Ltd.; Novartis Pharma Co.; Teijin Pharma Ltd.; Torii Pharmaceutical Co., Ltd., Nobunori Takahashi Speakers bureau: AbbVie Japan GK; Eisai Co. Ltd.; Mitsubishi Tanabe Pharma Co.; Pfizer Japan Inc.; Chugai Pharmaceutical Co., Ltd.; Eli Lilly Japan K.K.; Janssen Pharmaceutical K.K.; UCB Japan Co. Ltd.; Astellas Pharma Inc.; Bristol Myers Squibb Co. Ltd., Grant/research support from: Bristol Myers Squibb Co. Ltd., Naoto Tamura Speakers bureau: AbbVie Japan GK; Bristol Myers Squibb Co. Ltd.; Chugai Pharmaceutical Co. Ltd.; Eisai Co. Ltd.; Eli Lilly Japan K.K.; Glaxo Smith Kline K.K.; Janssen Pharmaceutical K.K.; Mitsubishi-Tanabe Pharma Co.; Novartis Pharma Co., Atsuo Nakajima: None declared, Ayako Nakajima Speakers bureau: AbbVie Japan GK; Actelion Pharmaceuticals Japan Ltd., Asahi Kasei Pharma Co., Astellas Pharma Inc., Ayumi Pharmaceutical Co., Bristol Myers Squibb Co., Ltd.,Chugai Pharmaceutical Co., Ltd., Eisai Co., Ltd., Eli Lilly Japan K.K., Glaxo Smith Kline K.K., Hisamitsu Pharmaceutical Co. Inc., Kyorin Pharmaceutical Co. Ltd., Mitsubishi Tanabe Pharma Co., Otsuka Pharmaceutical Co. Ltd., Pfizer Japan Inc., Teijin Pharma Ltd., Grant/research support from: Chugai Pharmaceutical Co., Ltd., Mitsubishi Tanabe Pharma Co., Pfizer Japan Inc., Hiroaki Matsuno Speakers bureau: Chugai Pharmaceutical Co., Ltd., Daiichi Sankyo Co., Ltd., Eli Lilly Japan K.K., Consultant of: Mochida Pharmaceutical Co., Ltd., Grant/research support from: Astellas Pharma Inc., Eli Lilly Japan K.K.; Janssen Pharmaceutical K.K, Naoto Tsujimoto Shareholder of: Eli Lilly, Employee of: Eli Lilly Japan K.K., Atsushi Nishikawa Shareholder of: Eli Lilly, Employee of: Eli Lilly Japan K.K., Taeko Ishii Shareholder of: Eli Lilly, Employee of: Eli Lilly Japan K.K., Tsutomu Takeuchi Speakers bureau: AbbVie Japan GK, Ayumi Pharmaceutical Co., Bristol Myers Squibb Co., Ltd., Chugai Pharmaceutical Co, Ltd. Daiichi Sankyo Co., Ltd. Eisai Co., Ltd. Eli Lilly Japan K.K.; Gilead Sciences, Inc. Janssen Pharmaceutical K.K.; Mitsubishi-Tanabe Pharma Co.; Novartis Pharma Co.; Pfizer Japan Inc.; Sanofi K.K.; UCB Japan Co., Ltd., Consultant of: AbbVie Japan GK, Astellas Pharma, Inc.; Chugai Pharmaceutical Co, Ltd.; Eli Lilly Japan K.K.; Eisai Co., Ltd.; Gilead Sciences, Inc.; Janssen Pharmaceutical K.K.; Mitsubishi-Tanabe Pharma Corp., Pfizer Japan Inc., Grant/research support from: AbbVie Japan GK, Asahikasei Pharma Corp., Chugai Pharmaceutical Co, Ltd., DNA Chip Research Inc.; Eisai Co., Ltd., Eli Lilly Japan K.K.; Mitsubishi-Tanabe Pharma Corp., UCB Japan Co., Ltd., Masataka Kuwana Speakers bureau: AbbVie Japan GK, Astellas Pharma Inc., Asahi Kasei Pharma Co., Boehringer-Ingelheim, Chugai Pharmaceutical Co., Ltd., Eisai Co., Ltd., Janssen Pharmaceutical K.K., Medical &Biological Laboratories Co., Ltd.; Mitsubishi Tanabe Pharma Co.; Mochida Pharmaceutical Co., Ltd., Nippon Shinyaku Co., Ltd.; Ono Pharmaceutical Co., Ltd.; Pfizer Japan Inc., Consultant of: Boehringer-Ingelheim, Chugai Pharmaceutical Co., Ltd., Corbus Pharmaceuticals Holdings, Inc.; Medical &Biological Laboratories Co., Ltd.; Mochida Pharmaceutical Co., Ltd., Grant/research support from: Boehringer-Ingelheim, Chugai Pharmaceutical Co., Ltd., Eisai Co., Ltd., Medical &Biological Laboratories Co., Ltd; Mitsubishi Tanabe Pharma Co., Ono Pharmaceutical Co., Ltd., Michiaki Takagi Speakers bureau: Yes, but sponsored lectures without COI in the academic meetings, only.

APA, Harvard, Vancouver, ISO, and other styles

35

Kravtsova, Marina E. "On Collections of the Chu Verses (chuci) of the 3rd–10th Centuries." Письменные памятники Востока 17, no. 3 (October 26, 2020): 25–33. http://dx.doi.org/10.17816/wmo46759.

Full text

Abstract:

The article deals with factual data on chuci (verses of Chu) collections, presented in the bibliographical treatises from the official historiographic works Suishu (Book of Sui), Jiutangshu (Old Book of Tang) and Xintangshu (New Book of Tang). Although most of the texts there recorded were irretrievably lost, the available information about the genre enables us to assume, firstly, a further growth in the popularity of chuci poetry in the spiritual life of the 3rd6th centuries and among a variety of groups of educated people: from court scholars to literati, who preferred a free-from-service lifestyle, and, secondly, the existence of a series of different versions of the Chuci collections. Thirdly, we may assume the formation of the commentary school of chuci, within which the most important directions of the future studies in the area have emerged.

APA, Harvard, Vancouver, ISO, and other styles

36

Decarriere, G., J. Pastor, D. Demoulin, G. Mouterde, C. Lukas, B. Combe, G. Mercier, J. Morel, and C. Daien. "OP0214 IMPACT OF A MULTI-MORBIDITY SCREENING AND PREVENTION PROGRAM IN CHRONIC INFLAMMATORY RHEUMATIC DISEASES ON THE ONE-YEAR HOSPITALIZATION RATE BASED ON AN ANALYSIS OF THE FRENCH NATIONAL HEALTH DATABASE." Annals of the Rheumatic Diseases 80, Suppl 1 (May 19, 2021): 128.2–129. http://dx.doi.org/10.1136/annrheumdis-2021-eular.3454.

Full text

Abstract:

Background:A screening program for multimorbidities started in 2014 at the Montpellier University Hospital for primary prevention in patients with chronic inflammatory rheumatic diseases (IRD).Objectives:The objective of this work was to assess the impact of this program on morbidity by comparing the hospitalization rate of those patients in the year following the screening to the one of patients with IRD who did not benefit from this program.Methods:Patients with IRD who benefit from the screening program in 2015, 2016 and 2017 were identified in the French national health database PMSI and matched to 3 controls living in the same area on age, sex, type of IRD, use of intravenous (IV) biologic (b) DMARDs and index date. The exclusion criteria were subjects in secondary prevention identified as history of myocardial infarction in the previous 5 years or use of antiplatelet therapy. The primary outcome was the rate of all-cause hospitalization in the following year. The secondary endpoints were hospitalizations for another reason than IRD (“non-IRD”) including those for cardiovascular [CV] events and major fractures. Hospitalization rates were compared between the two groups in the year after screening (or index date) and also between the year preceding screening and the year after for each group. Univariate and multivariate odds ratios (CI95%) were calculated, taking into account the medical history (hypertension, diabetes, heart failure, CV disease, COPD, major fractures in the 5 years preceding the index date) and hospitalizations in the previous year.Results:486 patients were identified and matched with 1458 controls. 67.08% had rheumatoid arthritis and 21.81% spondyloarthritis; 7% of them had IV bDMARDs. Unscreened patients had more hypertension (19% vs 10.1%), diabetes (9% vs 4.9%), heart failure (2.3% vs 0.4%) and “non-IRD” hospitalizations (78.5% vs 72.2%) in the 5 years preceding the index date. In the year following the index date, the percentages of “all causes” and “non-IRD” hospitalizations were significantly higher in non-screened than in screened patients (n = 1944, 64.8% versus 51%, Chi2 test, p <0.001; and 47.1% versus 37.9%, p <0.001 respectively). 17 (1.17%) cardiovascular events occurred in non-screened versus 2 (0.41%) in screened patients (n = 1944, Chi2 test, p = 0.14). There was no difference in the occurrence of CV events or major fractures between the 2 groups. In multivariate analysis, screening was associated with a 49% (0.51 [0.41-0.64]) reduction in “all causes” hospitalization and a 27% (0, 73 [0.58-0.91]) decrease in “non-IRD” hospitalization, with no difference for CV or fracture cardiological events. The risk factors associated with “non-IRD” hospitalization were: history of “non-IRD” hospitalization in the previous year (2.26 [1.63-3.13]), IV bDMARDs (1.69 [1, 14-2.53]) and age> 70 years (1.44 [1.02-2.03] vs <50 years). Hospitalization in the previous year for “all causes” or “non-IRD” was associated with rehospitalization in the following year in the non-screened group (p <0.001), but not in the screened group (p = 0.750 and p = 0.066 respectively).Conclusion:Our screening and prevention program was associated with a reduction in hospitalizations in the following year and a decrease in the risk of re-hospitalization compared to unscreened patients with IRD. This suggests a positive impact of performing systematic screening for multi-morbidities in IRD patients.Acknowledgements:We thank Pfizer for their financial supportDisclosure of Interests:guillaume decarriere: None declared, Jenica PASTOR: None declared, David DEMOULIN: None declared, Gael Mouterde Speakers bureau: Bristol-Myers Squibb; Gilead; Janssen; Lilly; Merck; Novartis; Pfizer; Roche-Chugai; and Sanofi, Grant/research support from: Pfizer, Cédric Lukas Speakers bureau: Abbvie, Amgen, Janssen, Lilly, MSD, Novartis, Pfizer, Roche-Chugai, UCB, Consultant of: Abbvie, Amgen, Janssen, Lilly, MSD, Novartis, Pfizer, Roche-Chugai, UCB, Grant/research support from: Pfizer, Novartis and Roche-Chugai, Bernard Combe Speakers bureau: AbbVie; Bristol-Myers Squibb; Gilead; Janssen; Lilly; Merck; Novartis; Pfizer; Roche-Chugai; and Sanofi, Consultant of: AbbVie; Bristol-Myers Squibb; Gilead; Janssen; Lilly; Merck; Novartis; Pfizer; Roche-Chugai; and Sanofi, Grant/research support from: Novartis, Pfizer, and Roche-Chugai, Grégoire Mercier: None declared, Jacques Morel Speakers bureau: AbbVie; Bristol-Myers Squibb; Gilead; Janssen; Lilly; Merck; Novartis; Pfizer; Roche-Chugai; and Sanofi, Consultant of: AbbVie; Bristol-Myers Squibb; Gilead; Janssen; Lilly; Merck; Novartis; Pfizer; Roche-Chugai; and Sanofi, Grant/research support from: Novartis, Pfizer, and Roche-Chugai, Claire Daien Speakers bureau: Pfizer, Roche-Chugai, Fresenius, BMS, MSD, Lilly, Novartis, Galapagos, Consultant of: Abivax, Abbbvie, BMS, Roche-Chugai, Grant/research support from: Pfizer, roche-chugai, fresenius, MSD

APA, Harvard, Vancouver, ISO, and other styles

37

Ebina, K., T. Hirano, Y. Maeda, W. Yamamoto, M. Hashimoto, K. Murata, T. Takeuchi, et al. "OP0025 DRUG RETENTION OF 7 BIOLOGICS AND TOFACITINIB IN BIOLOGICS-NAÏVE AND BIOLOGICS-SWITCHED PATIENTS WITH RHEUMATOID ARTHRITIS -THE ANSWER COHORT STUDY." Annals of the Rheumatic Diseases 79, Suppl 1 (June 2020): 18.2–19. http://dx.doi.org/10.1136/annrheumdis-2020-eular.814.

Full text

Abstract:

Background:EULAR recommendation announced that biological disease-modifying antirheumatic drugs (bDMARDs) and janus kinase inhibitors (JAKi) are considered as equivalent in the treatment of rheumatoid arthritis (RA). However, we still lack reliable evidence of direct comparison between these agents’ retention, which may reflect both effectiveness and safety.Objectives:The aim of this multi-center (7 university-related hospitals), retrospective study is to clarify retention rates and reasons for discontinuation of 7 bDMARDs and tofacitinib (TOF), one of the JAKi, in both bDMARDs-naïve and bDMARDs-switched cases.Methods:This study assessed 3,897 patients and 4,415 treatment courses of with bDMARDs and TOF from 2001 to 2019 (2,737 bDMARDs-naïve patients and 1,678 bDMARDs-switched patients [59.5% switched to their second agent], female 82.3%, baseline age 57.4 years, disease duration 8.5 years; rheumatoid factor positivity 78.4%; DAS28-ESR 4.3; concomitant prednisolone [PSL] 6.1 mg/day [42.4%] and methotrexate [MTX] 8.5 mg/week [60.9%]). Treatment courses included abatacept (ABT; n=663), adalimumab (ADA; n=536), certolizumab pegol (CZP; n=226), etanercept (ETN; n=856), golimumab (GLM; n=458), infliximab (IFX; n=724), tocilizumab (TCZ; n=851), and TOF (n=101/only bDMARDs-switched cases). Reasons for discontinuation were classified into four categories by each attending physician: 1) lack of effectiveness, 2) toxic adverse events, 3) non-toxic reasons, and 4) remission. Retention rates of each discontinuation reason were estimated at 36 months using the Kaplan-Meier method and adjusted for potential clinical confounders (age, sex, disease duration, concomitant PSL and MTX, starting date and number of switched bDMARDs) using Cox proportional hazards modeling.Results:Adjusted drug retention rates for each discontinuation reason were as follows: lack of effectiveness in the bDMARDs-naïve group (from 70.8% [CZP] to 85.1% [ABT]; P=0.001 between agents) and the bDMARDs-switched group (from 52.8% [CZP] to 78.7% [TCZ]; P<0.001 between agents). Toxic adverse events in the bDMARDs-naïve group (from 86.9% [IFX] to 96.3% [ABT]; P<0.001 between agents) and the bDMARDs-switched group (from 81.1% [ADA] to 95.4% [ETN]; P=0.01 between agents). Finally, overall retention rates excluding discontinuation for non-toxic reasons or remission ranged from 64.2% (IFX) to 82.0% (ABT) (P<0.001 between agents) in the bDMARDs-naïve group (figure a) and from 44.2% (ADA) to 66.8% (TCZ) (P<0.001 between agents) in the bDMARDs-switched group (figure b).Conclusion:Remarkable differences were observed in drug retention of 7 bDMARDs and TOF between bDMARDs-naïve and bDMARDs-switched cases.Disclosure of Interests:Kosuke Ebina Grant/research support from: KE has received research grants from Abbie, Asahi-Kasei, Astellas, Chugai, Eisai, Ono Pharmaceutical, and UCB Japan., Employee of: KE is affiliated with the Department of Musculoskeletal Regenerative Medicine, Osaka University, Graduate School of Medicine, which is supported by Taisho., Speakers bureau: KE has received payments for lectures from Abbie, Asahi-Kasei, Astellas, Ayumi, Bristol-Myers Squibb, Chugai, Eisai, Eli Lilly, Janssen, Mitsubishi-Tanabe, Ono Pharmaceutical, Sanofi, and UCB Japan., Toru Hirano Grant/research support from: TH received a research grant and/or speaker fee from Astellas, Chugai, Nippon Shinyaku, Abbvie, Eisai, and Ono Pharmaceutical, Speakers bureau: TH received a research grant and/or speaker fee from Astellas, Chugai, Nippon Shinyaku, Abbvie, Eisai, and Ono Pharmaceutical, Yuichi Maeda Grant/research support from: YM received a research grant and/or speaker fee from Eli Lilly, Chugai, Pfizer, Bristol-Myers Squibb, and Mitsubishi-Tanabe, Speakers bureau: YM received a research grant and/or speaker fee from Eli Lilly, Chugai, Pfizer, Bristol-Myers Squibb, and Mitsubishi-Tanabe, Wataru Yamamoto: None declared, Motomu Hashimoto Grant/research support from: Bristol-Myers Squibb, Eisai, and Eli Lilly and Company., Speakers bureau: Bristol-Myers Squibb and Mitsubishi Tanabe Pharma., Koichi Murata Grant/research support from: KMurata belong to a department that has been financially supported by four pharmaceutical companies (Mitsubishi-Tanabe, Chugai, AYUMI and UCB Japan)., Employee of: KMurata belong to a department that has been financially supported by four pharmaceutical companies (Mitsubishi-Tanabe, Chugai, AYUMI and UCB Japan)., Speakers bureau: KMurak has received speaking fees, and/or consulting fees from Eisai Co. Ltd, Chugai Pharmaceutical Co. Ltd., Pfizer Japan Inc, Bristol-Myers Squibb, Mitsubishi-Tanabe Pharma Corporation, UCB, Daiichi Sankyo Co. Ltd. and Astellas Pharma Inc., Tohru Takeuchi Grant/research support from: TT received a research grant from Chugai, CoverLetter and a speaker fee from Astellas, Chugai, Eisai, Mitsubishi-Tanabe, Abbvie, Bristol-Myers Squibb, Ayumi, Daiichi Sankyo, Eisai, Takeda, and Asahi-Kasei, Employee of: TT is affiliated with a department that is financially supported by six pharmaceutical companies (Mitsubishi-Tanabe, Chugai, Ayumi, Astellas, Eisai, and Takeda), Hideyuki Shiba: None declared, Yonsu Son: None declared, Hideki Amuro: None declared, Akira Onishi Speakers bureau: AO received a speaker fee from Chugai, Ono Pharmaceutical, Eli Lilly, Mitsubishi-Tanabe, Asahi-Kasei, and Takeda, Kengo Akashi: None declared, Ryota Hara Speakers bureau: RH received a speaker fee from AbbVie, Masaki Katayama: None declared, Keiichi Yamamoto: None declared, Atsushi Kumanogoh Grant/research support from: AK received a research grant and/or speaker fee from Mitsubishi-Tanabe, Chugai, Eisai, Asahi-Kasei, Astellas, Abbvie, Bristol-Myers Squibb, Ono Pharmaceutical, and Pfizer, Speakers bureau: AK received a research grant and/or speaker fee from Mitsubishi-Tanabe, Chugai, Eisai, Asahi-Kasei, Astellas, Abbvie, Bristol-Myers Squibb, Ono Pharmaceutical, and Pfizer, Makoto Hirao Speakers bureau: MHirao received a speaker fee from Astellas, Ono Pharmaceutical, Eli Lilly, Mitsubishi-Tanabe, Pfizer, Ayumi, and Takeda

APA, Harvard, Vancouver, ISO, and other styles

38

Sugihara, T., H. A. Uchida, H. Yoshifuji, Y. Maejima, T. Naniwa, Y. Katsumata, T. Okazaki, et al. "POS0336 PATTERNS OF LARGE-VESSEL LESIONS AND POOR TREATMENT OUTCOMES IN PATIENTS WITH LARGE-VESSEL GIANT CELL ARTERITIS." Annals of the Rheumatic Diseases 80, Suppl 1 (May 19, 2021): 395.2–396. http://dx.doi.org/10.1136/annrheumdis-2021-eular.824.

Full text

Abstract:

Background:Giant cell arteritis (GCA) is characterized by cranial symptoms and large-vessel lesions (LVL) in the aorta or its branches. We retrospectively analyzed the Japanese patients newly diagnosed as GCA between 2007 and 2014, and subsequently treated with glucocorticoid (GC). The imaging studies revealed that LVLs were observed in approximately half of the GCA patients, and the LVLs were significantly associated with the increased probability of poor treatment outcomes (1).Objectives:The objective of this study is to evaluate whether the distribution of LVLs of GCA was associated with poor treatment response.Methods:In a retrospective, multi-centric, nationwide registry of GCA patients treated with GCs between 2007 and 2014, 68 newly-diagnosed GCA with LVLs by imaging were detected. All investigators were members of Japan Research Committee of the Ministry of Health, Labour, and Welfare for Intractable Vasculitis (JPVAS). Poor treatment outcomes (non-achievement of clinical remission by week 24 or relapse during 104 weeks) were primarily evaluated. Cumulative rates and median time to the first event were analyzed by the Kaplan-Meier method and the log-rank test. Associated factors with the outcomes were analyzed by using the Cox proportional hazard model.Results:The mean age was 70.5 years, and 70.6% were women. Twenty-seven (39.7%) of the 68 patients were diagnosed as having GCA by both positive temporal artery biopsy and positive imaging, and 41 (60.3%) by positive imaging. Aortic lesions were detected in 72.1% (group 2, n=49) of the 68 GCA patients with LVLs. Patients without aortic lesions were categorized into two phenotypes: large-vessel GCA with subclavian lesions (group 1, n=9) and atypical large-vessel GCA without subclavian lesions (group 3, n=10). Cranial lesions were observed in 66.7%, 55.1%, and 80.0% in the group 1, 2, and 3, respectively. The initial mean dose (SD) of prednisolone was 0.74 (0.26) mg/kg/day, and 20.6 % received methotrexate for remission induction therapy. Baseline dose of GCs and mean time to achievement of low-dose GCs (prednisolone ≤ 5 mg/day) was not significantly different among the three groups.Overall, 35 (51.5%) of the 68 patients had the event of poor treatment outcomes. Eleven patients were not able to achieve clinical remission by week 24. Relapse after achievement of clinical remission was reported in total of 24 patients; 9 between week 0 and 24, 12 between week 24 and 52, 3 between week 52 and 104. The cumulative rate of events of poor treatment outcomes over the two years was 11.1% in patients with group 1, 55.3% in those with group 2, and 88.0% in those with group 3. Mean time to events was significantly different among the three groups. Multivariable analysis showed the risk of poor treatment outcomes was likely to decrease in the group 1 (hazard ratio 0.14 [95% CI 0.02-1.03], p=0.054), while it increased in the group 3 (hazard ratio 2.22 [95% CI 1.06-4.68], p=0.035).Conclusion:The distribution of LVLs were associated with poorer treatment outcomes. A half of the patients with aortic lesions had poor treatment outcomes while subclavian arteritis without aortic lesions had better clinical outcomes. Atypical large vessel-GCA without the aortic and subclavian artery involvement was the worst prognostic phenotype of LV-GCA. Extent of LVLs by imaging should be considered when determining the treatment strategy for GCA.References:[1]Sugihara T, et al. Arthritis Res Ther. 2020;22(1):72Acknowledgements:The authors would like to acknowledge Mitsuaki Isobe (Sakakibara Heart Institute), Yoshihiro Arimura (Kichijoji Asahi Hospital), and all the investigators in the Japan Research Committee of the Ministry of Health, Labour, and Welfare for Intractable Vasculitis (JPVAS). In addition to the authors, the following investigators and institutions participated in this study: Department of Internal Medicine, Juntendo University Koshigaya Hospital (Shigeto Kobayashi); Niigata Rheumatic Center (Satoshi Ito); Niigata Prefectural Shibata Hospital (Noriyuki Homma).Disclosure of Interests:takahiko sugihara Speakers bureau: TS has received honoraria from Abbvie Japan Co., Ltd., AsahiKASEI Co., Ltd., Astellas Pharma Inc., Ayumi Pharmaceutical, Bristol Myers Squibb K.K., Chugai Pharmaceutical Co., Ltd., Eli Lilly Japan K.K., Mitsubishi-Tanabe Pharma Co., Ono Pharmaceutical, Pfizer Japan Inc., Takeda Pharmaceutical Co. Ltd., and UCB Japan Co. Ltd., Grant/research support from: TS has received research grants from AsahiKASEI Co., Ltd., Daiichi Sankyo., and Ono Pharmaceutical., Haruhito A. Uchida Grant/research support from: HAU belongs to the Department of Chronic KidneyDisease and Cardiovascular Disease which is endowed by Chugai Pharmaceutical, MSD, Boehringer Ingelheim, and Kawanishi Holdings., Hajime Yoshifuji Speakers bureau: HY has received lecture fees from Chugai Pharmaceutical Co., Ltd. and Nihon Medi-Physics Co., Ltd., Yasuhiro Maejima Speakers bureau: YM have received honoraria from Chugai Pharmaceutical Co., Ltd.., Taio Naniwa Speakers bureau: TN has received lecture fees from Chugai Pharmaceutical Co., Ltd.., Grant/research support from: TN has received research grants from Chugai Pharmaceutical Co., Ltd.., Yasuhiro Katsumata Speakers bureau: YK has received honoraria from Chugai Pharmaceutical Co., Ltd., Glaxo-Smithkline K.K., Sanofi K.K., Pfizer Japan Inc., and Asahi Kasei Pharma Corp., Takahiro Okazaki Grant/research support from: TO has received research grants from Chugai Pharmaceutical Co., Ltd., Eisai Pharmaceutical., and Actelion, Jun Ishizaki: None declared, Yohko Murakawa Speakers bureau: YM has received honoraria from Abbvie, Astellas, Ayumi Pharmaceutical, Bristol Myers Squibb, Chugai Pharmaceutical, Eisai Pharmaceutical, Janssen Pharmaceutical, Kissei Pharmaceutical, Nippon Kayaku, Pfizer Pharmaceutical, Takeda Pharmaceutical, UCB Pharmaceutical, Grant/research support from: YM has received research grant support from Asahi Kasei Pharma, AbbVie Japan, Chugai Pharmaceutical, Daiichi Sankyo, Eisai Pharmaceutical, Mitsubishi Tanabe Pharma, Nippon Kayaku, Gilead Sciences Inc, Janssen Pharmaceutical, and Teijin Pharma., Noriyoshi Ogawa: None declared, Hiroaki Dobashi: None declared, Tetsuya Horita: None declared, Yoshiya Tanaka Speakers bureau: YT has received consulting fees, speaking fees, and/or honoraria from Daiichi-Sankyo, Astellas, Pfizer, Mitsubishi-Tanabe, Bristol-Myers, Chugai, YL Biologics, Eli Lilly, Sanofi, Janssen, UCB, Grant/research support from: YT has received research grants from Mitsubishi-Tanabe, Takeda, Bristol-Myers, Chugai, Astellas, Abbvie, MSD, Daiichi-Sankyo, Pfizer, Kyowa- Kirin, Eisai, Ono., Shunsuke Furuta: None declared, Tsutomu Takeuchi Speakers bureau: TT has served on speakers’ fees for AbbVie, Bristol-Myers Squibb, Chugai, Mitsubishi Tanabe, Pfizer, Astellas, Daiichi Sankyo, Eisai, Sanofi, Teijin, Takeda, and Novartis., Consultant of: TT has received consulting fees from Astra Zeneca, Eli Lilly, Novartis, Mitsubishi Tanabe, AbbVie, Nippon Kayaku, Janssen, Astellas, Taiho, Chugai, Taisho Toyama, GlaxoSmithKline, and UCB., Grant/research support from: TT has received research grants from Astellas, Chugai, Daiichi Sankyo, Takeda, AbbVie, Asahi Kasei, Mitsubishi Tanabe, Pfizer, Eisai, AYUMI, Nippon Kayaku, and Novartis., Yoshinori Komagata Speakers bureau: YK has received speakers’ fees from Bristol-Myers Squibb, Eli Lilly, Janssen, Novartis, Daiichi Sankyo, AbbVie, Nippon Shinyaku, Towa., Consultant of: YK has received consulting fees from Chugai, Kyowa Hakko Kirin, Asahi Kasei, UCB, Yoshikazu Nakaoka Speakers bureau: YN has received lecture fees from Astellas, Takeda, Daiichi Sankyo, Actelion, and Japan Blood Products Organization (JB)., Consultant of: YN has received consulting fees and/or lecture fees from AbbVie and Chugai, Grant/research support from: YN has received research grants from Chugai and Bayer Yakuhin, Ltd, masayoshi harigai Speakers bureau: MH has received speaker’s fee from AbbVie Japan GK, Ayumi Pharmaceutical Co., Boehringer Ingelheim Japan, Inc.,Bristol Myers Squibb Co., Ltd., Chugai Pharmaceutical Co., Ltd., Eisai Co., Ltd., Eli Lilly Japan K.K., GlaxoSmithKline K.K., Kissei Pharmaceutical Co., Ltd., Pfizer Japan Inc., Takeda Pharmaceutical Co., Ltd., and Teijin Pharma Ltd., Consultant of: MH is a consultant for AbbVie, Boehringer-ingelheim, Bristol Myers Squibb Co., Kissei Pharmaceutical Co.,Ltd. and Teijin Pharma., Grant/research support from: MH has received research grants from AbbVie Japan GK, Asahi Kasei Corp., Astellas Pharma Inc., Ayumi Pharmaceutical Co., Bristol Myers Squibb Co., Ltd., Chugai Pharmaceutical Co., Daiichi-Sankyo, Inc.,Eisai Co., Ltd., Kissei Pharmaceutical Co., Ltd., Mitsubishi Tanabe Pharma Co., Nippon Kayaku Co., Ltd., Sekiui Medical, Shionogi & Co., Ltd., Taisho Pharmaceutical Co., Ltd., Takeda Pharmaceutical Co., Ltd., and Teijin Pharma Ltd.

APA, Harvard, Vancouver, ISO, and other styles

39

백안남. "The Evolution, Cause and Mechanism of “Chufei”." Journal of Chinese Language and Literature ll, no. 55 (June 2010): 399–410. http://dx.doi.org/10.15792/clsyn..55.201006.399.

Full text

APA, Harvard, Vancouver, ISO, and other styles

40

MOSQUERA, L. ALBERTO, CHARLES A. SIMS, ROBERT P. BATES, and SEAN F. O'KEEFE. "Flavor and Stability of "Horchata De Chufas"." Journal of Food Science 61, no. 4 (July 1996): 856–61. http://dx.doi.org/10.1111/j.1365-2621.1996.tb12219.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

41

Tönshoff, H. K., and H. Noske. "Machine Tool Monitoring Applied to Lathe Chucks." CIRP Annals 39, no. 1 (1990): 429–32. http://dx.doi.org/10.1016/s0007-8506(07)61089-0.

Full text

APA, Harvard, Vancouver, ISO, and other styles

42

Noske, H. "Monitoring of Gripping Force in Lathe Chucks." IFAC Proceedings Volumes 24, no. 6 (September 1991): 581–86. http://dx.doi.org/10.1016/s1474-6670(17)51204-5.

Full text

APA, Harvard, Vancouver, ISO, and other styles

43

Lopes Filho, Brandel José Pacheco, Tiago Oviedo Frosi, and Claudia Silveira Lima. "Análise cinesiológica do movimento chudan gyaku zuki." Conexões 11, no. 3 (September 19, 2013): 36–49. http://dx.doi.org/10.20396/conex.v11i3.8637602.

Full text

Abstract:

O objetivo deste trabalho é realizar uma análise cinesiológica do Gyaku Zuki (soco invertido do Karate). Tal técnica foi selecionada após a realização de um levantamento na literatura sobre sua freqüência de repetição nos Shiteigata das competições da World Karate Federation. Os grupos musculares predominantemente ativados são, no braço que golpeia, depressores, rotadores superiores e abdutores da cintura escapular, flexores e flexores horizontais do ombro, extensores do cotovelo e pronadores da radioulnar. O benefício mais claro desse estudo é possibilitar um treinamento de força direcionado para os grupos musculares apresentados, que atuam diretamente na execução do soco de Karate.

APA, Harvard, Vancouver, ISO, and other styles

44

Spisak, April. "The Golden Dream of Carlo Chuchio (review)." Bulletin of the Center for Children's Books 61, no. 2 (2007): 71–72. http://dx.doi.org/10.1353/bcc.2007.0701.

Full text

APA, Harvard, Vancouver, ISO, and other styles

45

Oguoma, O. N. "Factors affecting gripping force of diaphragm chucks." International Journal of Machine Tools and Manufacture 30, no. 4 (January 1990): 497–508. http://dx.doi.org/10.1016/0890-6955(90)90002-z.

Full text

APA, Harvard, Vancouver, ISO, and other styles

46

Tomorug-Znaienko, Myroslava. "Restoration of the Self through History and Myth in Lina Kostenko’s “Marusia Churai”." Слово і Час, no. 6 (June 21, 2019): 39–45. http://dx.doi.org/10.33608/0236-1477.2019.06.39-45.

Full text

Abstract:

The paper analyzes Lina Kostenko’s historical novel in verse portraying the life of the 17th century Ukrainian minstrel poet Marusia Churai, condemned to death for poisoning her faithless lover. This work, which grows out of Kostenko’s individualized mythical perception of Marusia Churai legend, represents a unique individual construct in which the heroines’ quest for self-realization is kept in tune with the same yearning of the poetess herself; the author’s attitude towards the myth resembles the heroine’s relations with history. The narrative mode of the novel functions mainly in three aspects; these are the heroine’s confrontation with the carnivalized reality of her trial; her subjective journey inward, into the ruined self, when her execution was pending; and her objective pilgrimage outward, into the history of her ruined land, after getting pardon. The paper touches upon various aspects of the heroine’s perception of history. The main character is depicted as a witness of contemporary events and a bearer of the Word who keeps harmony with the sacred truth of the past. The Hetman’s ‘pardon’ allows Marusia to move freely through history in order to achieve a deeper understanding of her ruined land and seize its spirit. In the experience of the heroine the historical reality appears as versatile and polyphonic, at the same time remaining integral and inseparable from her personality. Kostenko asserts the rights of poets to create their own epochs, to recreate the past or present from within their own mythical experience, becoming thus not only myth-bearers but also mythmakers.

APA, Harvard, Vancouver, ISO, and other styles

47

&NA;. "Chugai Pharmaceutical has announced its approach to assessing safety measures for oseltamivir [Tamiflu],." Reactions Weekly &NA;, no. 1158 (June 2007): 2. http://dx.doi.org/10.2165/00128415-200711580-00005.

Full text

APA, Harvard, Vancouver, ISO, and other styles

48

&NA;. "Procarbazine [Natulan; Chugai Pharmaceutical] has been approved for a new indication in Japan,." Inpharma Weekly &NA;, no. 1479 (March 2005): 18. http://dx.doi.org/10.2165/00128413-200514790-00038.

Full text

APA, Harvard, Vancouver, ISO, and other styles

49

Znayenko, M. T. "Restoration of the Self through History and Myth in Lina Kostenko’s “Marusia Churai”." Canadian Slavonic Papers 32, no. 2 (June 1990): 166–76. http://dx.doi.org/10.1080/00085006.1990.11091933.

Full text

APA, Harvard, Vancouver, ISO, and other styles

50

&NA;. "Chugai Pharmaceutical has announced the launch of saquinavir [Invirase] 500mg tablets in Japan." Inpharma Weekly &NA;, no. 1556 (September 2006): 23. http://dx.doi.org/10.2165/00128413-200615560-00061.

Full text

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!